Press Releases

Alimera Sciences, Inc. a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch ILUVIEN® for non-infectious posterior uveitis in France, through its distribution partner, Horus Pharma S.A.S. (Horus). Horus has been granted pricing and reimbursement approval for ILUVIEN for p

Anthony Hayes, CEO of AIkido Pharma Inc.  announced the hiring of Carlos Aldavero as President of Dominari Financial, the recently formed financial services subsidiary of AIkido. Mr. Aldavero joins Dominari from Morgan Stanley where he was Associate Complex Manager overseeing one of the largest and most profitable business units at the venerable Wall St. firm. In this newly created role, Mr. Aldavero will be responsible for identifying strategic assets in the fintech and financ

BridgeBio Pharma, Inc. a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a new collaboration with Baylor College of Medicine to identify and translate cutting-edge research into potential therapies for patients with genetic diseases. “In these challenging times we believe it is more important than ever to be a stalwart partner to academic institutions working to serve patient populations big and small. We look forward to deve

Wellbeing Digital Sciences Inc. an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”), has entered into a research services agreement with Halucenex Life Sciences Inc. (“Halucenex”), a psychedelic subsidiary of Creso Pharma . “

CANbridge Pharmaceuticals Inc. a China and US-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that the first patient has been dosed in the CAN103 Phase 1/2 trial in treatment-naïve patients with Gaucher disease (GD) Types I and III in China. Bing Han MD, PhD, Chief Physician and Professor in the Department of Hematology at Peking Union Medical College Hospital in

The biopharmaceutical industry today adopted the " Berlin Declaration - Biopharmaceutical Industry's Vision for Equitable Access in the Event of a Pandemic. "' and made a proposal to world leaders that could help ensure the earliest possible delivery of pandemic vaccine, treatment and diagnostic supplies in future pandemics to those who need them most. The industry, which has been developing COVID-19 vaccines and therapies at record speed and historically unprecedented volum

PharmaCyte Biotech, Inc.a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypsCaps™ plus ifosfamide pancreatic cancer therapy for the treatment of malignant ascit

China Pharma Holdings, Inc. a specialty pharmaceutical company, today announced that on July 15, 2022, the Company submitted a plan of compliance to NYSE American LLC  to address the deficiency in the Company's stockholders' equity as pointed out in the letter from the Exchange dated June 15, 2022. As previously released in a press release dated June 22, 2022, according to the Letter, in order to maintain its listing, the Company must submit a plan of compliance by July

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-0390, an investigational emopamil-binding protein (EBP) inhibitor for the treatment of brain cancer. "This designation for DSP-0390 underscores the profound need for novel brain cancer treatment options," said Patricia S. Andrews, CEO and Global Head of Oncology, Sumitomo Pharma On

Recently, Kintor Pharma scientists published results of a study titled " Inhibitory Effects of GT0918 on Acute Lung Injury and the Molecular Mechanisms of Anti-inflammatory Response " in the preprint journal bioRxiv. The study demonstrated that pruxelutamide (GT0918) is an effective therapeutic drug for severe COVID-19 patients, in addition to mild to moderate COVID-19 patients treatment. The Kintor team found that pruxelutamide could reduce cytokine release and suppress i